Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
WuXi PharmaTech's Suzhou toxicology facility recives GLP certification from SFDA: Shanghai Friday, August 17, 2012, 18:00 Hrs [IST] WuXi PharmaTech, a leading pharmaceutical, biot ...
CHALK RIVER, Ontario, July 15, 2025 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that the Chalk River ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results